Oral Mucositis refers to an erythematous and ulcerative lesion of the oral mucosa seen in patients with cancer being treated with chemotherapy, and/or with radiation therapy to fields comprising of the oral cavity.
&nbsp;
This can lead to various problems, including pain, nutritional problems as a result of the inability to eat, and increased risk of infection because of open sores in the mucosa. It has a significant effect on the patient&rsquo;s quality of life and can be dose-limiting. This condition generally begins 5-10 days following the initiation of chemotherapy and lasts one week to six weeks or more.
&nbsp;
Oral Mucositis diagnosis is typically based on the appearance, location, and timing of oral lesions, and the medical history, which may show a medication or treatment form that is highly linked with the disease.
&nbsp;
Oral Mucositis Epidemiological Segmentation&nbsp;
The Epidemiological Segmentation of Oral Mucositis in 7MM from 2017 to 2030 is segmented as:-
<ul>
<li>Total Incident Cases</li>
<li>Grade-specific Incident Cases</li>
<li>Total Treated Cases</li>
</ul>
&nbsp;
Oral Mucositis Epidemiology&nbsp;
<ul>
<li>The total Oral Mucositis incident cases in 7MM in 2017 were 1,418,879</li>
<li>The total treated cases of Oral Mucositis in 7MM in 2017 were 1,021,399</li>
</ul>
&nbsp;
<a style="background-color: transparent; color: #0066cc;" href="https://www.delveinsight.com/report-store/oral-mucositis-om-market" target="_blank" rel="noopener noreferrer">Oral Mucositis Market</a>
The therapeutic Oral Mucositis market in 7MM in 2017 was USD 1,052.7 million&nbsp;&nbsp;
&nbsp;
Oral Mucositis Market Drivers
<ul>
<li>Increasing Incidence of Cancer patients</li>
<li>Ongoing Research and Development</li>
<li>Robust Pipeline Activity</li>
</ul>
&nbsp;
Oral Mucositis Market Barriers
<ul>
<li>Limited awareness about the disease</li>
<li>Lack of diagnostic methods</li>
<li>The high cost of treatment</li>
</ul>
&nbsp;
Oral Mucositis Emerging Drugs
The emerging drugs of the Oral Mucositis market are
<ul>
<li>Brilacidin</li>
<li>EC-18</li>
<li>Cooral System</li>
<li>CareMin650</li>
<li>Validive (Clonidine Lauriad)</li>
<li>MuReva Phototherapy System</li>
<li>RRx-001</li>
<li>SGX942</li>
<li>Avasopasem (GC4419)</li>
</ul>
And many others.
&nbsp;
Oral Mucositis Key Players
The key players in the Oral Mucositis market are
<ul>
<li>Innovation Pharmaceuticals</li>
<li>Enzychem Lifesciences Corporation</li>
<li>BrainCool</li>
<li>NeoMedLight</li>
<li>Monopar Therapeutics</li>
<li>MuReva (Lumitex)</li>
<li>EpicentRx</li>
<li>Prothex Pharma</li>
<li>Soligenix</li>
<li>Galera Therapeutics</li>
</ul>
And many others.

Oral Mucositis Market

Oral Mucositis Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.